000			01662 a2200445 4500
005			20250515104409.0
264		0	_c20090109
008			200901s 0 0 eng d
022			_a0302-2838
024	7		_a10.1016/j.eururo.2007.12.041 _2doi
040			_aNLM _beng _cNLM
100	1		_aMargulis, Vitaly
245	0	0	_aCytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? _h[electronic resource]
260			_bEuropean urology _cSep 2008
300			_a489-92 p. _bdigital
500			_aPublication Type: Editorial
650	0	4	_aAngiogenesis Inhibitors _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aBevacizumab
650	0	4	_aCarcinoma, Renal Cell _xpathology
650	0	4	_aClinical Trials as Topic
650	0	4	_aCombined Modality Therapy
650	0	4	_aHumans
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aKidney Neoplasms _xpathology
650	0	4	_aNephrectomy _xmethods
650	0	4	_aProtein Kinases _xtherapeutic use
650	0	4	_aPyrazoles _xtherapeutic use
650	0	4	_aPyrimidines _xtherapeutic use
650	0	4	_aPyrroles _xtherapeutic use
650	0	4	_aSunitinib
650	0	4	_aSurvival Analysis
650	0	4	_aTOR Serine-Threonine Kinases
650	0	4	_aVascular Endothelial Growth Factor A _xantagonists & inhibitors
700	1		_aWood, Christopher G
773	0		_tEuropean urology _gvol. 54 _gno. 3 _gp. 489-92
856	4	0	_uhttps://doi.org/10.1016/j.eururo.2007.12.041 _zAvailable from publisher's website
999			_c17714118 _d17714118